MeiraGTx Holdings plc Induced Conversion of Convertible Debt Expense
MeiraGTx Holdings plc (MGTX) reported Induced Conversion of Convertible Debt Expense of $553.50 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:InducedConversionOfConvertibleDebtExpense · last filed 2019-03-26
- MeiraGTx Holdings plc induced conversion of convertible debt expense for fiscal 2017 was $553.50K.
| Period end | Induced Conversion of Convertible Debt Expense 12 month |
|---|---|
| 2017-12-31 | $553.50K 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |